|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.630 - 0.880|
|52 Week Range||0.630 - 0.880|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cerulean Pharma Inc. and Daré Bioscience Operations, Inc. today announced the closing of the transactions contemplated by the stock purchase agreement entered into by the companies on March 19, 2017.
Cerulean Pharma Inc. and Daré Bioscience, Inc. today announced that Daré Founder and CEO Sabrina Martucci Johnson mailed the following letter to Cerulean stockholders
Cerulean Pharma Inc. today urged stockholders of record at the close of business on June 9, 2017 to vote FOR all of the proposals at the upcoming special meeting of stockholders to be held on July 19, 2017.
Cerulean Pharma Inc. today announced that the company mailed the following letter from President and Chief Executive Officer Christopher D. T. Guiffre to the company’
Cerulean Pharma Inc. , and Daré Bioscience, Inc., a privately-held, clinical-stage healthcare company advancing products for women’s reproductive health, today announced that Sabrina Martucci Johnson, Daré Founder and CEO, is receiving two awards.
Cerulean Pharma Inc. , today announced jointly with Daré Bioscience that the companies will hold a joint conference call to discuss the definitive share purchase agreement under which the stockholders of Daré Bioscience will become the majority owners of Cerulean.
Cerulean Pharma Inc. and Daré Bioscience, Inc., a privately-held, clinical-stage pharmaceutical company advancing products for women’s reproductive health, today announced that the two companies, together with the equityholders of Daré Bioscience, have entered into a definitive stock purchase agreement under which the equityholders of Daré Bioscience will become the majority owners of Cerulean.
NEW YORK, NY / ACCESSWIRE / March 14, 2017 / The Biotech Sector is seeing the arrival of some new competitors, with one company continuing to overperform and another set to have its business absorbed or ...
Cerulean Pharma Inc. , a clinical-stage company developing nanoparticle-drug conjugates , today announced that its Board of Directors is conducting a comprehensive review of strategic alternatives focused on maximizing stockholder value.